Elevation Oncology, Inc. (ELEV)
NASDAQ: ELEV · IEX Real-Time Price · USD
3.645
-0.235 (-6.06%)
At close: Apr 25, 2024, 4:00 PM
3.660
+0.015 (0.41%)
After-hours: Apr 25, 2024, 4:52 PM EDT
Elevation Oncology Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Elevation Oncology stock have an average target of 7.25, with a low estimate of 6.00 and a high estimate of 8.00. The average target predicts an increase of 98.90% from the current stock price of 3.65.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ELEV stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
---|---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
Buy | 2 | 2 | 2 | 2 | 3 | 3 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 1 | 1 | 1 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 4 | 4 | 4 | 3 | 4 | 4 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +64.61% | Apr 9, 2024 |
JMP Securities | JMP Securities | Buy Reiterates $7 | Buy | Reiterates | $7 | +92.04% | Mar 7, 2024 |
Wedbush | Wedbush | Buy Maintains $5 → $8 | Buy | Maintains | $5 → $8 | +119.48% | Mar 7, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +64.61% | Mar 7, 2024 |
JMP Securities | JMP Securities | Buy Initiates $7 | Buy | Initiates | $7 | +92.04% | Mar 1, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.87
from -1.34
EPS Next Year
-0.90
from -0.87
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | n/a | n/a | n/a | 12.6M | 53.2M |
Avg | n/a | n/a | n/a | 4.3M | 31.5M |
Low | n/a | n/a | n/a | n/a | 3.9M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | 1,125.4% |
Avg | - | - | - | - | 625.1% |
Low | - | - | - | - | -11.2% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -0.79 | -0.65 | -0.53 | -0.53 | -0.33 |
Avg | -0.87 | -0.90 | -1.14 | -0.57 | -0.35 |
Low | -0.90 | -1.27 | -1.91 | -0.61 | -0.37 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | - |
Avg | - | - | - | - | - |
Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.